3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
18
Prostatic Neoplasms
18
Sarcoma
5
Neoplasms
4
Uterine Neoplasms
2
Rhabdomyosarcoma
2
Rectal Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Dysplasia
1
To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
1
Retinoblastoma
1
Prostate Cancer With Intermediate Risk
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Metastatic Malignant Female Reproductive System Neoplasm
1
Lung Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
1
Endometrial Adenocarcinoma
1
Desmoplastic Small Round Cell Tumor
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
6
Cisplatin
5
Radiotherapy
4
Paclitaxel
3
Nivolumab
3
lenvatinib
2
Specimen Handling
2
Platinum
2
Papillomavirus Vaccines
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Gemcitabine
2
Carboplatin
2
CTLA-4 Antigen
2
Bleomycin
2
Bevacizumab
2
1,2-diaminocyclohexaneplatinum II citrate
2
zimberelimab
1
rocakinogene sifuplasmid
1
liposomal doxorubicin
1
durvalumab
1
dostarlimab
1
cemiplimab
1
belzutifan
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alovudine
1
aldesleukin
1
Watchful Waiting
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Vulvar Neoplasms
×
Brachytherapy
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts